Dr Janet Scott

Affiliate (School of Infection & Immunity)

Biography

Dr Janet Scott is Clinical Lecturer in Infectious Disease at the MRC-University of Glasgow Centre for Virus Research.

Dr Scott trained in Parasitology at the University of Glasgow and holds a PhD in the cellular immune-epidemiology of Schistosomiasis, also from the University of Glasgow, with research in The Gambia, Zimbabwe and Senegal.

After gaining a degree in Medicine at the University of Oxford, she joined the TB Vaccine team as a clinical academic in parallel with her clinical training.

During the Ebola 2014-16 epidemic, she was the clinical lead for the Brincidofovir Trial (Monrovia, Liberia), and Convalescent Plasma (Freetown, Sierra Leone) and was also a member of the clinical trial team for the Tekmira trial.

She is now engaged in the pharmacokinetic/pharmacodynamics analysis of data gathered during these trials and developing methods for dose optimizing drugs for category 4 viruses and studying post Ebola and post COVID syndromes.

Research interests

Virus image CVR Supporting COVID-19 Research Response

Dr Scott's main interests are: post viral sequalae focusing on 'LongCOVID' and Post Ebola Syndrome targeting particularly post viral fatigue.

She is also interested in optimising the doses of anti-viral therapeutics using pharmacokinetic and pharmacodynamic in vitro and in silico models with a focus for Lassa and Ebola viruses.

Selected Media

Voice of America podcast with Joe De Capua discussing Ebola and research stating that 80 per cent of survivors suffer disabilities one year after being discharged from hospital.

Listen here: https://soundcloud.com/post-ebola-syndrome

BBC World Service audio documentary discussing whether the Ebola Virus can live on undetected (9 October 2015).

Listen here (06:43-11:35): http://www.bbc.co.uk/p0343hb5

BBC News Hour show discussing if WHO declaring the Ebola epidemic officially over was really the good news the region had been waiting for with flare-ups likely (14 January 2016)

Listen here: http://www.bbc.co.uk/programmes/p03fgzv8

Publications

List by: Type | Date

Jump to: 2024 | 2023 | 2022 | 2021 | 2020 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2009 | 2008 | 2007 | 2004 | 2003 | 2001 | 2000 | 1998

Number of items: 95.

2024

Pazukina, E. et al. (2024) Long covid: a global health issue - a prospective, cohort study set in four continents. BMJ Global Health, 9(10), e015245. (doi: 10.1136/bmjgh-2024-015245)

Greenwood, D. C. et al. (2024) Physical, cognitive and social triggers of symptom fluctuations in people living with long COVID: an intensive longitudinal cohort study. Lancet Regional Health - Europe, 46, 101082. (doi: 10.1016/j.lanepe.2024.101082)

Smith, A. et al. (2024) Psychometric analysis of the modified COVID-19 Yorkshire Rehabilitation Scale (C19-YRSm) in a prospective multicentre study. BMJ Open Respiratory Research, 11(1), e002271. (doi: 10.1136/bmjresp-2023-002271) (PMID:38724221)

Liew, F. et al. (2024) Large-scale phenotyping of patients with long COVID post-hospitalization reveals mechanistic subtypes of disease. Nature Immunology, 25(4), pp. 607-621. (doi: 10.1038/s41590-024-01778-0) (PMID:38589621)

Sivan, M. et al. (2024) Long COVID clinical severity types based on symptoms and functional disability: A longitudinal evaluation. Journal of Clinical Medicine, 13(7), 1908. (doi: 10.3390/jcm13071908)

Lee, C. et al. (2024) Prevalence of orthostatic intolerance in Long Covid clinic patients: a multicentre observational study. Journal of Medical Virology, 96(3), e29486. (doi: 10.1002/jmv.29486) (PMID:38456315)

Pazukhina, E. et al. (2024) Event rates and incidence of Post-COVID-19 condition in hospitalised SARS-CoV-2 positive children and young people and controls across different pandemic waves: exposure-stratified prospective cohort study in Moscow (StopCOVID). BMC Medicine(22), 48. (doi: 10.1186/s12916-023-03221-x) (PMID:38302974) (PMCID:PMC10835884)

Elneima, O. et al. (2024) Cohort profile: Post-hospitalisation COVID-19 study (PHOSP-COVID). International Journal of Epidemiology, 53(1), dyad165. (doi: 10.1093/ije/dyad165) (PMCID:PMC10859139)

Brackel, C. L.H. et al. (2024) International care programs for Pediatric Post-COVID Condition (Long COVID) and the way forward. Pediatric Research, (doi: 10.1038/s41390-023-03015-0) (PMID:38287106) (Early Online Publication)

Battaglini, D., White, N. M., Premraj, L., Wanjiru Citarella, B., Merson, L., Robba, C., Thomson, D., Cho, S.-M. and ISARIC Clinical Characterization Group, (2024) Long-term neurological symptoms after acute COVID-19 illness requiring hospitalization in adult patients: insights from the ISARIC-COVID-19 follow-up study. Journal of Neurology, 271(1), pp. 79-86. (doi: 10.1007/s00415-023-12133-y) (PMID:38055020) (PMCID:PMC10769963)

Cho, S.-M. et al. (2024) Sex differences in post-acute neurological sequelae of SARS-CoV-2 and symptom resolution in adults after COVID-19 hospitalization: An international multicenter prospective observational study. Brain Communications, 6(2), fcae036. (doi: 10.1093/braincomms/fcae036) (PMID:38444907) (PMCID:PMC10914448)

Darbyshire, J. et al. (2024) Improving quality in adult long Covid services: findings from the LOCOMOTION quality improvement collaborative. Clinical Medicine, (Accepted for Publication)

2023

Hastie, C. E. et al. (2023) True prevalence of long-COVID in a nationwide, population cohort study. Nature Communications, 14, 7892. (doi: 10.1038/s41467-023-43661-w) (PMID:38036541) (PMCID:PMC10689486)

Baillie, J.K. et al. (2023) Multiorgan MRI findings after hospitalisation with COVID-19 in the UK (C-MORE): a prospective, multicentre, observational cohort study. Lancet Respiratory Medicine, 11(11), pp. 1003-1019. (doi: 10.1016/S2213-2600(23)00262-X) (PMID:37748493) (PMCID:PMC7615263)

Taquet, M. et al. (2023) Acute blood biomarker profiles predict cognitive deficits 6 and 12 months after COVID-19 hospitalization. Nature Medicine, (doi: 10.1038/s41591-023-02525-y) (PMID:37653345) (Early Online Publication)

Jackson, C. et al. (2023) Effects of sleep disturbance on dyspnoea and impaired lung function following hospital admission due to COVID-19 in the UK: a prospective multicentre cohort study. Lancet Respiratory Medicine, 11(8), pp. 673-684. (doi: 10.1016/S2213-2600(23)00124-8) (PMID:37072018) (PMCID:PMC10156429)

Hastie, C. E. et al. (2023) Natural history of long-COVID in a nationwide, population cohort study. Nature Communications, 14, 3504. (doi: 10.1038/s41467-023-39193-y) (PMID:37311808) (PMCID:PMC10263377)

Pauley, E., Drake, T. M., Sigfrid, L., Lone, N., Harrison, E. M., Baillie, J. K., Scott, J. T. , Walsh, T. S., Semple, M. G. and Docherty, A. B. (2023) Recovery from Covid-19 critical illness: a secondary analysis of the ISARIC4C CCP-UK cohort study and the RECOVER trial. Journal of the Intensive Care Society, 24(2), pp. 162-169. (doi: 10.1177/17511437211052226) (PMID:37255989) (PMCID:PMC10225805)

Kartsonaki, C. et al. (2023) Characteristics and outcomes of an international cohort of 600 000 hospitalized patients with COVID-19. International Journal of Epidemiology, 52(2), pp. 355-376. (doi: 10.1093/ije/dyad012) (PMID:36850054) (PMCID:PMC10114094)

Parker, E. et al. (2023) SARS-CoV-2 antibody responses associate with sex, age and disease severity in previously uninfected people admitted to hospital with COVID-19: an ISARIC4C prospective study. Frontiers in Immunology, 14, 1146702. (doi: 10.3389/fimmu.2023.1146702) (PMID:37056776) (PMCID:PMC10087108)

Turtle, L. et al. (2023) Outcome of COVID-19 in hospitalised immunocompromised patients: an analysis of the WHO ISARIC CCP-UK prospective cohort study. PLoS Medicine, 20(1), e1004086. (doi: 10.1371/journal.pmed.1004086) (PMID:36719907) (PMCID:PMC9928075)

2022

Vink, E. et al. (2022) Viral co-infections in hospitalised COVID-19 patients recruited to the ISARIC WHO CCP-UK study. Open Forum Infectious Diseases, 9(11), ofac531. (doi: 10.1093/ofid/ofac531) (PMID:36381618) (PMCID:PMC9619746)

Hastie, C. E. et al. (2022) Outcomes among confirmed cases and a matched comparison group in the Long-COVID in Scotland Study. Nature Communications, 13, 5663. (doi: 10.1038/s41467-022-33415-5) (PMID:36224173) (PMCID:PMC9556711)

Hastie, C. E. et al. (2022) Do we need consent to obtain consent? Public and participant feedback to using personal health data for recruitment. Journal of Epidemiology and Community Health, 76(8), pp. 697-698. (doi: 10.1136/jech-2022-219214) (PMID:35672086) (PMCID:PMC9279750)

The PHOSP-COVID Collaborative Group, (2022) Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study. Lancet Respiratory Medicine, 10(8), pp. 761-775. (doi: 10.1016/S2213-2600(22)00127-8) (PMID:35472304) (PMCID:PMC9034855)

ISARIC Clinical Characterization Group, et al. (2022) ISARIC-COVID-19 dataset: a prospective, standardized, global dataset of patients hospitalized with COVID-19. Scientific Data, 9(1), 454. (doi: 10.1038/s41597-022-01534-9) (PMID:35908040) (PMCID:PMC9339000)

Pazukhina, E. et al. (2022) Prevalence and risk factors of post-COVID-19 condition in adults and children at 6 and 12 months after hospital discharge: a prospective, cohort study in Moscow (StopCOVID). BMC Medicine, 20, 244. (doi: 10.1186/s12916-022-02448-4) (PMID:35794549) (PMCID:PMC9257572)

Munblit, D. et al. (2022) A core outcome set for post-COVID-19 condition in adults for use in clinical practice and research: an international Delphi consensus study. Lancet Respiratory Medicine, 10(7), pp. 715-724. (doi: 10.1016/S2213-2600(22)00169-2) (PMID:35714658) (PMCID:PMC9197249)

Knight, S. R. et al. (2022) Prospective validation of the 4C prognostic models for adults hospitalised with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol. Thorax, 77(6), pp. 606-615. (doi: 10.1136/thoraxjnl-2021-217629) (PMID:34810237) (PMCID:PMC8610617)

Stewart, A. et al. (2022) Pandemic, epidemic, endemic: B cell repertoire analysis reveals unique anti-viral responses to SARS-CoV-2, Ebola and Respiratory Syncytial Virus. Frontiers in Immunology, 13, 807104. (doi: 10.3389/fimmu.2022.807104) (PMID:35592326) (PMCID:PMC9111746)

Närhi, F. et al. (2022) Implementation of corticosteroids in treatment of COVID-19 in the ISARIC WHO Clinical Characterisation Protocol UK: prospective, cohort study. Lancet Digital Health, 4(4), e220-e234. (doi: 10.1016/S2589-7500(22)00018-8) (PMID:35337642) (PMCID:PMC8940185)

Rosadas, C. et al. (2022) Detection and quantification of antibody to SARS CoV 2 receptor binding domain provides enhanced sensitivity, specificity and utility. Journal of Virological Methods, 302, 114475. (doi: 10.1016/j.jviromet.2022.114475) (PMID:35077719) (PMCID:PMC8782753)

Munblit, D. et al. (2022) Studying the post-COVID-19 condition: research challenges, strategies, and importance of Core Outcome Set development. BMC Medicine, 20, 50. (doi: 10.1186/s12916-021-02222-y) (PMID:35114994) (PMCID:PMC8813480)

Osmanov, I. M. et al. (2022) Risk factors for long covid in previously hospitalised children using the ISARIC Global follow-up protocol: A prospective cohort study. European Respiratory Journal, 59(2), 2101341. (doi: 10.1183/13993003.01341-2021) (PMID:34210789) (PMCID:PMC8576804)

Sullivan, M. K. et al. (2022) Acute kidney injury in patients hospitalised with COVID-19 from the ISARIC WHO CCP-UK Study: a prospective, multicentre cohort study. Nephrology Dialysis Transplantation, 37(2), pp. 271-284. (doi: 10.1093/ndt/gfab303) (PMID:34661677) (PMCID:PMC8788218)

Young, M., Crook, H., Scott, J. and Edison, P. (2022) COVID-19: virology, variants, and vaccines. BMJ Medicine, 1(1), e000040. (doi: 10.1136/bmjmed-2021-000040) (PMID:36936563) (PMCID:PMC9951271)

Reyes, L. F. et al. (2022) Clinical characteristics, risk factors and outcomes in patients with severe COVID-19 registered in the ISARIC WHO Clinical Characterisation Protocol: a prospective, multinational, multicentre, observational study. ERJ Open Research, 8(1), 00552-2021. (doi: 10.1183/23120541.00552-2021) (PMID:35169585) (PMCID:PMC8669808)

2021

Niemi, M. E. K. et al. (2021) Mapping the human genetic architecture of COVID-19. Nature, 600(7889), pp. 472-477. (doi: 10.1038/s41586-021-03767-x) (PMID:34237774) (PMCID:PMC8674144)

Evans, R. A. et al. (2021) Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study. Lancet Respiratory Medicine, 9(11), pp. 1275-1287. (doi: 10.1016/S2213-2600(21)00383-0) (PMID:34627560) (PMCID:PMC8497028)

Abdukahil, S. A. et al. (2021) COVID-19 symptoms at hospital admission vary with age and sex: results from the ISARIC prospective multinational observational study. Infection, 49(5), pp. 889-905. (doi: 10.1007/s15010-021-01599-5) (PMID:34170486) (PMCID:PMC8231091)

Michelen, M. et al. (2021) Characterising Long Covid: a living systematic review. BMJ Global Health, 6, e005427. (doi: 10.1136/bmjgh-2021-005427) (PMID:34580069) (PMCID:PMC8478580)

Munblit, D. et al. (2021) Incidence and risk factors for persistent symptoms in adults previously hospitalised for COVID-19. Clinical and Experimental Allergy, 51(9), pp. 1107-1120. (doi: 10.1111/cea.13997) (PMID:34351016)

Sigfrid, L. et al. (2021) Long Covid in adults discharged from UK hospitals after Covid-19: a prospective, multicentre cohort study using the ISARIC WHO Clinical Characterisation Protocol. Lancet Regional Health - Europe, 8, 100186. (doi: 10.1016/j.lanepe.2021.100186) (PMID:34386785) (PMCID:PMC8343377)

Russell, C. D. et al. (2021) Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study. Lancet Microbe, 2(8), e354-e365. (doi: 10.1016/S2666-5247(21)00090-2) (PMID:34100002) (PMCID:PMC8172149)

Drake, T. M. et al. (2021) Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study. Lancet, 398(10296), pp. 223-237. (doi: 10.1016/S0140-6736(21)00799-6) (PMID:34274064) (PMCID:PMC8285118)

Gupta, R. K. et al. (2021) Development and validation of the ISARIC 4C Deterioration model for adults hospitalised with COVID-19: a prospective cohort study. Lancet Respiratory Medicine, 9(4), pp. 349-359. (doi: 10.1016/S2213-2600(20)30559-2) (PMID:33444539) (PMCID:PMC7832571)

Carson, G. and Long Covid Forum Group, (2021) Research priorities for Long Covid: refined through an international multi-stakeholder forum. BMC Medicine, 19(1), 84. (doi: 10.1186/s12916-021-01947-0) (PMID:33785027) (PMCID:PMC8009733)

Scott, J. et al. (2021) ISARIC4C: Multicentre cohort study on symptoms and quality of life following hospitalisation for COVID-19 - preliminary results, 25 February 2021. Documentation. Scientific Advisory Group for Emergencies.

Sigfrid, L. et al. (2021) What is the recovery rate and risk of long-term consequences following a diagnosis of COVID-19? A harmonised, global longitudinal observational study protocol. BMJ Open, 11(3), e043887. (doi: 10.1136/bmjopen-2020-043887) (PMID:33692181) (PMCID:PMC7948153)

Pairo-Castineira, E. et al. (2021) Genetic mechanisms of critical illness in Covid-19. Nature, 591(7848), pp. 92-98. (doi: 10.1038/s41586-020-03065-y) (PMID:33307546)

Adaken, C. et al. (2021) Ebola virus antibody decay–stimulation in a high proportion of survivors. Nature, 590, pp. 468-472. (doi: 10.1038/s41586-020-03146-y) (PMID:33505020) (PMCID:PMC7839293)

Munblit, D. et al. (2021) The risk of overlooking children during the COVID-19 pandemic: Paediatric Long-COVID may be a ticking time bomb. Lancet Child and Adolescent Health, (Accepted for Publication)

2020

Hanna, C. R. et al. (2020) Glasgow Early Treatment Arm Favirpiravir (GETAFIX) for adults with early stage COVID-19: A structured summary of a study protocol for a randomised controlled trial. Trials, 21(935), (doi: 10.1186/s13063-020-04891-1) (PMID:33213530) (PMCID:PMC7675389)

Knight, S. R. et al. (2020) Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score. British Medical Journal, 2020, 370. (doi: 10.1136/bmj.m3339) (PMID:32907855)

Swann, O. V. et al. (2020) Clinical characteristics of children and young people admitted to hospital with covid-19 in United Kingdom: prospective multicentre observational cohort study. British Medical Journal, 370, m3249. (doi: 10.1136/bmj.m3249) (PMID:32960186) (PMCID:PMC7488201)

Holgate, S. et al. (2020) Preparing for a challenging winter 2020/21. Technical Report. Academy of Medical Sciences, London.

Harrison, E. M. et al. (2020) Ethnicity and outcomes from COVID-19: the ISARIC CCP-UK prospective observational cohort study of hospitalised patients. SSRN Electronic Journal, (doi: 10.2139/ssrn.3618215) (Submitted)

Akhvlediani, T. et al. (2020) Global outbreak research: harmony not hegemony. Lancet Infectious Diseases, 20(7), pp. 770-772. (doi: 10.1016/S1473-3099(20)30440-0) (PMID:32502433) (PMCID:PMC7266570)

Docherty, A. B. et al. (2020) Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. British Medical Journal, 369, m1985. (doi: 10.1136/bmj.m1985) (PMID:32444460)

Scott, J. T. , Sharma, R., Meredith, L. W., Dunning, J., Moore, C. E., Sahr, F., Ward, S., Goodfellow, I. and Horby, P. (2020) Pharmacokinetics of TKM-130803 in Sierra Leonean patients with Ebola virus disease: plasma concentrations exceed target levels, with drug accumulation in the most severe patients. EBioMedicine, 52, 102601. (doi: 10.1016/j.ebiom.2019.102601) (PMID:31953031) (PMCID:PMC7033524)

2018

Howlett, P. J. et al. (2018) Case series of severe neurologic sequelae of Ebola virus disease during epidemic, Sierra Leone. Emerging Infectious Diseases, 24(8), pp. 1412-1421. (doi: 10.3201/eid2408.171367) (PMID:30014839)

Steptoe, P. J. et al. (2018) Multimodal imaging and spatial analysis of Ebola retinal lesions in 14 survivors of Ebola virus disease. JAMA Ophthalmology, 136(6), pp. 689-693. (doi: 10.1001/jamaophthalmol.2018.1248) (PMID:29800941)

Tedder, R. S. et al. (2018) Detection, characterization, and enrollment of donors of Ebola convalescent plasma in Sierra Leone. Transfusion, 58(5), pp. 1289-1298. (doi: 10.1111/trf.14580) (PMID:29572862) (PMCID:PMC5947131)

Jagadesh, S., Fletcher, T. E., Sevalie, S., Weigel, R. and Scott, J. T. (2018) Reply to Steptoe et al. Clinical Infectious Diseases, 66(8), p. 1319. (doi: 10.1093/cid/cix980) (PMID:29126296)

Steptoe, P. J., Scott, J. T. , Sahr, F., Vandy, M., Harding, S. P., Beare, N. A. V. and Semple, M. G. (2018) Re: Shantha et al.: Ophthalmic manifestations and causes of vision impairment in Ebola virus disease survivors in Monrovia, Liberia (Ophthalmology. 2017;124:170-177). Ophthalmology, 125(3), e19. (doi: 10.1016/j.ophtha.2017.09.009) (PMID:29458832)

Jagadesh, S., Sevalie, S., Fatoma, R., Sesay, F., Sahr, F., Faragher, B., Semple, M. G., Fletcher, T. E., Weigel, R. and Scott, J. T. (2018) Disability among Ebola survivors and their close contacts in Sierra Leone: a retrospective case-controlled cohort study. Clinical Infectious Diseases, 66(1), pp. 131-133. (doi: 10.1093/cid/cix705) (PMID:29020205) (PMCID:PMC5833946)

2017

Steptoe, P. J., Scott, J. T. and Semple, M. G. (2017) Reply to Lee and colleagues—Viral posterior uveitis. Survey of Ophthalmology, 62(4), pp. 404-445. (doi: 10.1016/j.survophthal.2016.12.008) (PMID:28624250)

Steptoe, P. J., Scott, J. T. , Harding, S. P., Beare, N. A. V., Semple, M. G., Vandy, M. J. and Sahr, F. (2017) Ocular complications in survivors of the Ebola outbreak in Guinea. American Journal of Ophthalmology, 181, p. 180. (doi: 10.1016/j.ajo.2017.05.029) (PMID:28760310) (PMCID:PMC5833943)

Steptoe, P. J. et al. (2017) Novel retinal lesion in Ebola survivors, Sierra Leone, 2016. Emerging Infectious Diseases, 23(7), pp. 1102-1109. (doi: 10.3201/eid2307.161608) (PMID:28628441) (PMCID:PMC5512503)

Glynn, J. R. et al. (2017) Asymptomatic infection and unrecognised Ebola virus disease in Ebola-affected households in Sierra Leone: a cross-sectional study using a new non-invasive assay for antibodies to Ebola virus. Lancet Infectious Diseases, 17(6), pp. 645-653. (doi: 10.1016/S1473-3099(17)30111-1) (PMID:28256310)

Scott, J. T. and Semple, M. G. (2017) Ebola virus disease sequelae: a challenge that is not going away. Lancet Infectious Diseases, 17(5), pp. 470-471. (doi: 10.1016/S1473-3099(17)30027-0) (PMID:28094207) (PMCID:PMC5818139)

Howlett, P., Walder, A., Lisk, D., N'jai, A., Lado, M., Brown, C., Sevalie, S., Sesay, F.R., Semple, M.G. and Scott, J.T. (2017) Neurological and Psychiatric Manifestations of Post Ebola Syndrome in Sierra Leone. Spring Meeting for Clinician Scientists in Training 2017, London, UK, 23 Feb 2017. S48. (doi: 10.1016/S0140-6736(17)30444-0)

2016

Glod, J. W. et al. (2016) Experimental treatment of Ebola virus disease with brincidofovir. PLoS ONE, 11(9), e0162199. (doi: 10.1371/journal.pone.0162199) (PMID:27611077) (PMCID:PMC5017617)

Bustinduy, A. L. et al. (2016) Population pharmacokinetics and pharmacodynamics of praziquantel in Ugandan children with intestinal schistosomiasis: higher dosages are required for maximal efficacy. mBio, 7(4), e00227-16. (doi: 10.1128/mBio.00227-16) (PMID:27507822) (PMCID:PMC4992966)

Burki, T. K., Crozier, I., Lado, M. and Scott, J. (2016) Post-Ebola syndrome. Lancet Infectious Diseases, 16(7), pp. 780-781. (doi: 10.1016/S1473-3099(15)00259-5) (PMID:27352759)

Scott, J. T. , Sesay, F. R., Massaquoi, T. A., Idriss, B. R., Sahr, F. and Semple, M. G. (2016) Post-Ebola syndrome, Sierra Leone. Emerging Infectious Diseases, 22(4), pp. 641-646. (doi: 10.3201/eid2204.151302) (PMID:26983037) (PMCID:PMC4806950)

Scott, J. T. (2016) Ebola epidemic over but flare-ups likely. [Audio]

2015

Scott, J. T. (2015) Can the Ebola virus live on undetected? [Audio]

2014

Bustinduy, A., King, C., Scott, J. , Appleton, S., Sousa-Figueiredo, J. C., Betson, M. and Stothard, J. R. (2014) HIV and schistosomiasis co-infection in African children. Lancet Infectious Diseases, 14(7), pp. 640-649. (doi: 10.1016/S1473-3099(14)70001-5) (PMID:24747019)

2013

Rowland, R. et al. (2013) Safety and immunogenicity of an FP9-vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCG-vaccinated healthy adults. Human Vaccines and Immunotherapeutics, 9(1), pp. 50-62. (doi: 10.4161/hv.22464) (PMID:23143773) (PMCID:PMC3667946)

2012

Scott, J. T. , Scally, C., Peden, N. and Macleod, M. (2012) Voltage-gated potassium channel antibody-related encephalopathy: a case which may extend the documented phenotype of this condition. BMJ Case Reports, 2012, 0720114476. (doi: 10.1136/bcr.07.2011.4476) (PMID:22693327) (PMCID:PMC4543178)

2009

Karita, E. et al. (2009) CLSI-derived hematology and biochemistry reference intervals for healthy adults in Eastern and Southern Africa. PLoS ONE, 4(2), e4401. (doi: 10.1371/journal.pone.0004401) (PMID:19197365) (PMCID:PMC2632744)

2008

Scott, J. (2008) Should I apply for an academic foundation programme? Foundation Years, 4(2), pp. 85-86. (doi: 10.1016/j.mpfou.2008.03.002)

2007

Vereecken, K., Naus, C. W. A., Polman, K., Scott, J. T. , Diop, M., Gryseels, B. and Kestens, L. (2007) Associations between specific antibody responses and resistance to reinfection in a Senegalese population recently exposed to Schistosoma mansoni. Tropical Medicine and International Health, 12(3), pp. 431-444. (doi: 10.1111/j.1365-3156.2006.01805.x) (PMID:17313515)

2004

Debacker, M., Aguiar, J., Steunou, C., Zinsou, C., Meyers, W. M., Scott, J. T. , Dramaix, M. and Portaels, F. (2004) Mycobacterium ulcerans disease: role of age and gender in incidence and morbidity. Tropical Medicine and International Health, 9(12), pp. 1297-1304. (doi: 10.1111/j.1365-3156.2004.01339.x) (PMID:15598261)

Debacker, M., Aguiar, J., Steunou, C., Zinsou, C., Meyers, W. M., Guédénon, A., Scott, J. T. , Dramaix, M. and Portaels, F. (2004) Mycobacterium ulcerans Disease (Buruli Ulcer) in Rural Hospital, Southern Benin, 1997–2001. Emerging Infectious Diseases, 10(8), pp. 1391-1398. (doi: 10.3201/eid1008.030886) (PMID:15496239) (PMCID:PMC3320395)

Chatterjee, S., Mbaye, A., Alfidja, A. T., Weyler, J., Scott, J. T. , Van Damme, P., Van De Vijver, K., Deelder, A. and Van Marck, E. A.E. (2004) Circulating levels of the neuropeptide hormone somatostatin may determine hepatic fibrosis in Schistosoma mansoni infections. Acta Tropica, 90(2), pp. 191-203. (doi: 10.1016/j.actatropica.2003.12.002) (PMID:15177146)

Scott, J. T. , Johnson, R. C., Aguiar, J., Debacker, M., Kestens, L., Guedenon, A., Gryseels, B. and Portaels, F. (2004) Schistosoma haematobium infection and Buruli ulcer. Emerging Infectious Diseases, 10(3), pp. 551-552. (doi: 10.3201/eid1003.020514) (PMID:15116714) (PMCID:PMC3322796)

Scott, J. T. , Vereecken, K., Diakhate, M. M., Vanagt, T., Sambou, V., Diop, M., Ly, A., Vercruysse, J., Gryseels, B. and Kestens, L. (2004) Are the cellular immune responses of children and adults with Schistosoma mansoni infection intrinsically different? Cytokines produced ex vivo in response to antigens and mitogens. Parasite Immunology, 26(1), pp. 29-36. (doi: 10.1111/j.0141-9838.2004.00680.x) (PMID:15198643)

2003

Mduluza, T. et al. (2003) Contrasting cellular responses in Schistosoma haematobium infected and exposed individuals from areas of high and low transmission in Zimbabwe. Immunology Letters, 88(3), pp. 249-256. (doi: 10.1016/S0165-2478(03)00088-9) (PMID:12941484)

Scott, J.T. et al. (2003) Corrigendum. Tropical Medicine and International Health, 8(6), p. 580. (doi: 10.1046/j.1365-3156.2003.01068.x)

Scott, J.T. et al. (2003) Human water contacts patterns in Schistosoma mansoni epidemic foci in northern Senegal change according to age, sex and place of residence, but are not related to intensity of infection. Tropical Medicine and International Health, 8(2), pp. 100-108. (doi: 10.1046/j.1365-3156.2003.00993.x) (PMID:12581433)

2001

Scott, J. T. , Turner, C.M. R., Mutapi, F., Woolhouse, M. E.J., Ndhlovu, P. D. and Hagan, P. (2001) Cytokine responses to mitogen and Schistosoma haematobium antigens are different in children with distinct infection histories. Parasite Immunology, 23(10), pp. 519-526. (doi: 10.1046/j.1365-3024.2001.00409.x) (PMID:11696162)

2000

Scott, J. T. , Turner, C. M. R., Mutapi, F., Woolhouse, M. E.J., Chandiwana, S. K., Mduluza, T., Ndhlovu, P. D. and Hagan, P. (2000) Dissociation of interleukin-4 and interleukin-5 production following treatment for Schistosoma haematobium infection in humans. Parasite Immunology, 22(7), pp. 341-348. (doi: 10.1046/j.1365-3024.2000.00311.x) (PMID:10886718)

1998

Mutapi, F., Ndhlovu, P. D., Hagan, P., Spicer, J. T. , Mduluza, T., Turner, C. M. R., Chandiwana, S. K. and Woolhouse, M. E.J. (1998) Chemotherapy accelerates the development of acquired immune responses to Schistosoma haematobium infection. Journal of Infectious Diseases, 178(1), pp. 289-293. (doi: 10.1086/517456) (PMID:9652458)

This list was generated on Thu Nov 21 04:59:15 2024 GMT.

Jump to: Articles | Research Reports or Papers | Conference or Workshop Item | Audio

Number of items: 95.

Articles

Pazukina, E. et al. (2024) Long covid: a global health issue - a prospective, cohort study set in four continents. BMJ Global Health, 9(10), e015245. (doi: 10.1136/bmjgh-2024-015245)

Elneima, O. et al. (2024) Cohort profile: Post-hospitalisation COVID-19 study (PHOSP-COVID). International Journal of Epidemiology, 53(1), dyad165. (doi: 10.1093/ije/dyad165) (PMCID:PMC10859139)

Darbyshire, J. et al. (2024) Improving quality in adult long Covid services: findings from the LOCOMOTION quality improvement collaborative. Clinical Medicine, (Accepted for Publication)

Young, M., Crook, H., Scott, J. and Edison, P. (2022) COVID-19: virology, variants, and vaccines. BMJ Medicine, 1(1), e000040. (doi: 10.1136/bmjmed-2021-000040) (PMID:36936563) (PMCID:PMC9951271)

Niemi, M. E. K. et al. (2021) Mapping the human genetic architecture of COVID-19. Nature, 600(7889), pp. 472-477. (doi: 10.1038/s41586-021-03767-x) (PMID:34237774) (PMCID:PMC8674144)

Michelen, M. et al. (2021) Characterising Long Covid: a living systematic review. BMJ Global Health, 6, e005427. (doi: 10.1136/bmjgh-2021-005427) (PMID:34580069) (PMCID:PMC8478580)

Pairo-Castineira, E. et al. (2021) Genetic mechanisms of critical illness in Covid-19. Nature, 591(7848), pp. 92-98. (doi: 10.1038/s41586-020-03065-y) (PMID:33307546)

Adaken, C. et al. (2021) Ebola virus antibody decay–stimulation in a high proportion of survivors. Nature, 590, pp. 468-472. (doi: 10.1038/s41586-020-03146-y) (PMID:33505020) (PMCID:PMC7839293)

Akhvlediani, T. et al. (2020) Global outbreak research: harmony not hegemony. Lancet Infectious Diseases, 20(7), pp. 770-772. (doi: 10.1016/S1473-3099(20)30440-0) (PMID:32502433) (PMCID:PMC7266570)

Jagadesh, S., Fletcher, T. E., Sevalie, S., Weigel, R. and Scott, J. T. (2018) Reply to Steptoe et al. Clinical Infectious Diseases, 66(8), p. 1319. (doi: 10.1093/cid/cix980) (PMID:29126296)

Glod, J. W. et al. (2016) Experimental treatment of Ebola virus disease with brincidofovir. PLoS ONE, 11(9), e0162199. (doi: 10.1371/journal.pone.0162199) (PMID:27611077) (PMCID:PMC5017617)

Burki, T. K., Crozier, I., Lado, M. and Scott, J. (2016) Post-Ebola syndrome. Lancet Infectious Diseases, 16(7), pp. 780-781. (doi: 10.1016/S1473-3099(15)00259-5) (PMID:27352759)

Scott, J. (2008) Should I apply for an academic foundation programme? Foundation Years, 4(2), pp. 85-86. (doi: 10.1016/j.mpfou.2008.03.002)

Scott, J.T. et al. (2003) Corrigendum. Tropical Medicine and International Health, 8(6), p. 580. (doi: 10.1046/j.1365-3156.2003.01068.x)

Research Reports or Papers

Holgate, S. et al. (2020) Preparing for a challenging winter 2020/21. Technical Report. Academy of Medical Sciences, London.

Conference or Workshop Item

Audio

Scott, J. T. (2016) Ebola epidemic over but flare-ups likely. [Audio]

Scott, J. T. (2015) Can the Ebola virus live on undetected? [Audio]

This list was generated on Thu Nov 21 04:59:15 2024 GMT.

Grants

Grants and Awards listed are those received whilst working with the University of Glasgow.

Understanding relapsing remitting Long COVID
Wellcome Trust
2022 - 2023
Defining and understanding the longer-term effects of COVID-19: A mixed methods study exploring the frequency, nature, and impact of 'long COVID' in the Scottish population.
Office of the Chief Scientific Adviser
2021 - 2023
Defining and understanding the longer-term effects of COVID-19: A mixed methods study exploring the frequency, nature, and impact of 'long COVID' in the Scottish population.
Public Health Scotland
2021 - 2023
Glasgow Early Treatment Arm Favipiravir (GETAFIX): a randomised controlled study of favipiravir in COVID-19 hospitalised patients
Chief Scientist Office
2020 - 2021
Development of an in vitro system for dose and regimen optimisation of therapeutics for Lassa Fever
Tenovus Scotland
2018 - 2020

A head and shoulders shot of Dr Janet Scott against a plain white background

Media Appearances

BBC The Nine - Wednesday 21 April 2021

Dr Scott appeared on the Wednesday 21 April edition of BBC Scotland's The Nine to discusses the GETAFIX trial testing favipiravir against Covid-19.

Speaking to presenter Martin Geissler about the antiviral drug that she hopes will be effective in treating Covid, Dr Scott said: "Favipiravir was first developed for influenza in Japan and we are hoping it will work for Covid-19.”

BBC Five Live: Lunchtime Show - Wednesday 21 April 2021

Dr Scott was interviewed by Naga Munchetty on the Wednesday 21 April edition of BBC 5 Live's Lunchtime Show, in which they discuss the GETAFIX trial testing favipiravir against Covid-19.

We use cookies

Necessary cookies

Analytics cookies

Clarity

Dr Janet Scott

Biography

Research interests

Publications

2024

2023

2022

2021

2020

2018

2017

2016

2015

2014

2013

2012

2009

2008

2007

2004

2003

2001

2000

1998

Articles

Research Reports or Papers

Conference or Workshop Item

Audio

Grants

Media Appearances